Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)

NCT00038506 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT00038506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00038506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)
Lead sponsor
ViiV Healthcare
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2002
Completion date
August 31, 2004
Enrollment
100
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection